Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Completed · Phase 2
Conditions studied: Pancreatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with imatinib mesylate works as first-line therapy in treating patients with locally advanced or metastatic pancreatic cancer.
Key facts
- Study ID
- NCT00161213
- Run by
- University of Medicine and Dentistry of New Jersey
- People needed
- 44
- Starts
- 2005-09-01
- Expected to finish
- 2010-10-01
- Last updated by the study team
- 2023-08-14
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
- CentraState Medical Center — Freehold, New Jersey, United States
- Cancer Institute of New Jersey at Hamilton — Hamilton, New Jersey, United States
- Jersey Shore Cancer Center at Jersey Shore University Medical Center — Neptune City, New Jersey, United States
- Central Jersey Oncology Group — New Brunswick, New Jersey, United States
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States
- Saint Peter's University Hospital — New Brunswick, New Jersey, United States
- New Jersey Medical School — Newark, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.